To provide a model animal developing a fatal graft versus host disease (GVHD), a screening method for a preventing and treating agent of the GVHD by using such the GVHD model animal, a receptor protein PIR-B and its gene recognizing a MHC class I molecule, and a preventing and treating agent of the GVHD by using a human homolog of the PIR-B as an active ingredient.
This method for screening the preventing and treating agent of the GVHD by using a mouse losing a function of expressing the PIR-B by an inactivation with a gene mutation such as destruction, delete, substitution, etc., of the whole or part of an endogenous gene of a non-human animal encoding the PIR-B, as the GVHD model animal. As the human homolog of the PIR-B, an LILRB1, LILRB2, etc., can be mentioned.
NAKAMURA AKIRA
JPN6009047880, Ｎａｔ． Ｉｍｍｕｎｏｌ．, 2002, ３（６）, ｐ．５４２−５４８
JPN6009047883, Ｊ． Ｉｍｍｕｎｏｌ．, 2002, １６９（１０）, ｐ．５５８１−５５８９
Next Patent: METHOD FOR PRODUCING POLY-3-HYDROXYALKANOIC ACID